The latest list of medicines to be referred to the National Institute for Health and Clinical Excellence (NICE) for appraisal includes Janssen’s Velcade (bortezomib) andBayer HealthCare’s Xarelto (rivaroxaban).
NICE will examine Velcade’s clinical and cost effectiveness when used for induction therapy prior to high-dose chemotherapy and autologous stem cell transplantation for the treatment of multiple myeloma. It will also look at the drug’s use as consolidation therapy after autologous stem cell transplantation for treating the condition.
Other products on the latest list for appraisal of clinical and cost effectiveness by NICE are:
– Novartis’ Ilaris (canakinumab) for the treatment of systemic juvenile idiopathic arthritis;
– Sanofi/Isis Pharmaceuticals’ Kynamro (mipomersen) for the prevention of cardiovascular events in people with homozygous or severe heterozygous familial hypercholesterolemia;
– Bayer HealthCare’s Xarelto (rivaroxaban) for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome;
– Pfizer’s oral Janus kinase inhibitor (JAK) tofacitinib for the treatment of rheumatoid arthritis after the failure of disease-modifying anti-rheumatic drugs (DMARDs);
– Napp Pharmaceuticals’ Levact (bendamustine) in combination with rituximab for the first-line treatment of mantle cell lymphoma; and
– Alexza Pharmaceuticals’ inhaled antipsychotic Adasuve (loxapine) for the treatment of acute agitation and disturbed behaviours in people with schizophrenia or bipolar disorder.
